Recent phase II clinical trials, such as TEDOVA (NCT04713514) and DOVACC (NCT04742075), are investigating the role of neoantigenic or telomerase-targeted therapeutic vaccines (OSE2101, UV1) in combination with PD-1/PD-L1 inhibitors and PARP inhibitors in patients with recurrent ovarian cancer, aiming to enhance immune memory and prolong disease-free survival [88,89]. Here, CD274 is linked to ovarian carcinoma.